Shares of AbbVie (ABBV) plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of 澳洲幸运5官方开奖结果体彩网:Phase 2 clinical trials.

AbbVie said the trials did n𓂃ot show a statistically significant improvem♉ent in symptoms compared with the placebo group at week 6.

"While we are disappointed with the results, we are continuing to analyze the data to determine next steps," AbbVie Chief Scientific Officer Dr. Roopal Thakkar said.

Abbvie's shares were recently down 12%. Meanwhile, shares of Bristol Myers Squibb (BMY), makers of 澳洲幸运5官方🌸开奖结果体彩网:rece😼ntly approved schizophrenia treatment Cobenfy, soared 12%.

AbbVi𒅌e shares are up about 13% this year, while those of Bristol Myers Squibb have risen 18%.